United Therapeutics Corporation Reports 2016 Fourth Quarter And Annual Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
United Therapeutics Corp. (UTHR) PT Raised to $175 at Oppenheimer
February 23, 2017 9:27 AM ESTOppenheimer raised its price target on United Therapeutics Corp. (NASDAQ: UTHR) to $175.00 (from $160.00) while maintaining a Outperform rating.
Analyst Hartaj Singh commented, "United Therapeutics (UTHR) reported 4Q16 sales/earnings and provided a business update to investors earlier today. The company reported a... More
United Therapeutics (UTHR) Tops Q4 EPS by 51c
February 22, 2017 6:01 AM ESTUnited Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $4.12, $0.51 better than the analyst estimate of $3.61. Revenue for the quarter came in at $409 million versus the consensus estimate of $415.51 million.
"Our annual 2016 financial results reflect continued growth as net revenues reached $1.6 billion and earnings exceeded $700... More
